PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. Article

Full Text via DOI: 10.1200/JCO.2018.36.15_suppl.TPS3115 Web of Science: 000442916007582
Industry Collaboration

Cited authors

  • Vaena, Daniel A.; Chaves, Jorge; Vogelzang, Nicholas J.; Matrana, Marc Ryan; Gabayan, A. Eli; Riese, Matthew John; Cho, Daniel C.; Tagliaferri, Mary Ann; Zalevsky, Jonathan; Xie, Sunny; Hoch, Ute; RIZWAN, A. H. S. A. N. N. A. Q. I.; Aung, Sandra; Imperiale, Michael; Schwarz, James K.

Publication date

  • 2018

Published in

International Standard Serial Number (ISSN)

  • 0732-183X


  • 36


  • 15